Beta-only IL-2 therapy for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Infections, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can give written consent before any study tests or procedures
- Your cancer is a locally advanced or metastatic solid tumor confirmed by a pathology test (biopsy or scan of cells)
- You have at least one measurable tumor spot that can be followed on CT or MRI
- Your overall strength is good (ECOG 0 to 1) and you’re expected to live at least 12 weeks
- Your organs (like blood counts, liver, and kidneys) are strong enough for treatment
- If you can become pregnant: you must have a negative pregnancy test and use very effective birth control; you must not be breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy (natural killer cells) made from a donor, combined with low-dose IL-15 (a protein that helps these cells work) and sometimes with pembrolizumab (Keytruda), for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a new drug called BT02 for people with advanced solid tumors who have not had any cancer treatment before. It aims to see if BT02 is safe and how well it works.
This Phase 1/2 study tests an experimental medicine (RNK05047) in people with advanced solid tumors or diffuse large B‑cell lymphoma whose standard treatments haven’t worked or can’t be tolerated. It may help shrink tumors and improve control of the disease, but early-phase trials also focus on safety and dosing.
This early-phase study tests a new treatment in people with advanced (locally advanced or metastatic) solid tumors that have worsened or cannot be treated with standard therapies. It may help shrink tumors or slow growth, and it also helps doctors learn the safest way to use the medicine.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
This trial tests an experimental oral drug (7HP349) combined with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced solid tumors. It aims to see if the combination is safe and effective in shrinking tumors.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.